Overview
Drug-induced pulmonary fibrosis (DIPF) refers to lung scarring caused by certain medications, leading to impaired lung function and respiratory symptoms 1. This condition is distinct from radiation-induced fibrosis, though both involve tissue damage leading to fibrotic changes 1.Diagnosis
Clinical history of drug exposure is crucial 1.
High-resolution computed tomography (HRCT) often shows characteristic fibrotic patterns 1.
Pulmonary function tests (PFTs) reveal restrictive or mixed ventilatory defects 1.
Bronchoalveolar lavage (BAL) and lung biopsy may be necessary for definitive diagnosis in complex cases 1.Management
Discontinue the offending drug immediately upon suspicion 1.
Corticosteroids are often first-line therapy, typically starting with prednisone at 0.5-1 mg/kg/day 1.
Immunosuppressive agents like cyclophosphamide or mycophenolate mofetil may be used adjunctively in severe cases 1.
Oxygen therapy and supportive care for respiratory symptoms are essential 1.Special Populations
No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.Key Recommendations
Identify and discontinue the causative drug promptly upon suspicion of DIPF (Evidence: Expert opinion 1).
Initiate corticosteroid therapy with prednisone at 0.5-1 mg/kg/day for managing inflammation (Evidence: Expert opinion 1).
Consider immunosuppressive therapy for severe cases refractory to corticosteroids (Evidence: Expert opinion 1).References
1 McClelland M, VanLoock JS, Patterson JW, Greer KE. Radiation-induced morphea occurring after fluoroscopy. Journal of the American Academy of Dermatology 2002. link